Sheue-yann Cheng
|
Dr. Sheue-yann Cheng
|
Dr. Sheue-yann Cheng (PhD) is the Section Chief of the Gene Regulation, Laboratory of Molecular Biology (LMB), Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Cheng received her PhD from the University of California, San Francisco Medical Center. She was a research associate, mentored by Dr. Elwood Jensen, at the Ben May Laboratory for Cancer Research, at the University of Chicago. She accepted a second postdoctoral fellowship, mentored by Drs. Hans Cahnmann and Jacob Robbins, at the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, NIH. She was later tenured as a Principal Investigator and promoted to be a Section Chief of the Gene Regulation Section, LMB, NCI.
Dr. Cheng’s lifetime interest has been to unravel the complex molecular actions of thyroid hormone. She pioneered the development of mouse models to understand the molecular basis of diseases caused by mutations of thyroid hormone nuclear receptors. Her intensive studies of mouse models of resistance to thyroid hormone (RTHβ and RTHa) resulted in the discovery that mutations of thyroid hormone nuclear receptor subtypes lead to different human diseases and the distinct in vivo molecular actions of TR isoform mutants. Dr. Cheng also developed preclinical mouse models of metastatic follicular thyroid cancer and anaplastic thyroid cancer. She identified molecular targets for potential treatment of thyroid cancer, especially for anaplastic thyroid cancer for which the treatment is very limited. Her findings are being translated from the bench to clinical trials.
For her outstanding scientific accomplishments, Dr. Cheng has received many awards including the prestigious Sidney H. Ingbar Distinguished Lectureship Award of The American Thyroid Association (ATA), Distinguished Service Award of ATA, and the John B. Stanbury Thyroid Pathophysiology Medal of ATA, the Pitt-Rivers Lectureship Award of The British Thyroid Association, the Charles Harkin Award of NCI, three-time Merit Awards of the NIH, and the Abbott Thyroid Research Clinical Fellowship Mentor Award of the Endocrine Society.
Dr. Cheng was recognized nationally and internationally as a leader in her field. She served as a program chair of ATA, and represented ATA as a member of the Program Committee for the 13th and 16th International Thyroid Congress. She organized and served on the Program Committee of the International Workshops of Resistance to Thyroid hormone. She was a regular member of Molecular and Cellular Endocrinology Study Session of NIH and an adviser for women scientists at the CCR, NCI. She is an Associate Editor of Thyroid and an Associate Editor-in-Chief of the American Journal of Cancer Research. She serves on the Editorial Board of many journals. She holds patents, and licenses of her inventions and has published more than 250 papers in peer-reviewed journals.
Dr. Cheng’s lifetime interest has been to unravel the complex molecular actions of thyroid hormone. She pioneered the development of mouse models to understand the molecular basis of diseases caused by mutations of thyroid hormone nuclear receptors. Her intensive studies of mouse models of resistance to thyroid hormone (RTHβ and RTHa) resulted in the discovery that mutations of thyroid hormone nuclear receptor subtypes lead to different human diseases and the distinct in vivo molecular actions of TR isoform mutants. Dr. Cheng also developed preclinical mouse models of metastatic follicular thyroid cancer and anaplastic thyroid cancer. She identified molecular targets for potential treatment of thyroid cancer, especially for anaplastic thyroid cancer for which the treatment is very limited. Her findings are being translated from the bench to clinical trials.
For her outstanding scientific accomplishments, Dr. Cheng has received many awards including the prestigious Sidney H. Ingbar Distinguished Lectureship Award of The American Thyroid Association (ATA), Distinguished Service Award of ATA, and the John B. Stanbury Thyroid Pathophysiology Medal of ATA, the Pitt-Rivers Lectureship Award of The British Thyroid Association, the Charles Harkin Award of NCI, three-time Merit Awards of the NIH, and the Abbott Thyroid Research Clinical Fellowship Mentor Award of the Endocrine Society.
Dr. Cheng was recognized nationally and internationally as a leader in her field. She served as a program chair of ATA, and represented ATA as a member of the Program Committee for the 13th and 16th International Thyroid Congress. She organized and served on the Program Committee of the International Workshops of Resistance to Thyroid hormone. She was a regular member of Molecular and Cellular Endocrinology Study Session of NIH and an adviser for women scientists at the CCR, NCI. She is an Associate Editor of Thyroid and an Associate Editor-in-Chief of the American Journal of Cancer Research. She serves on the Editorial Board of many journals. She holds patents, and licenses of her inventions and has published more than 250 papers in peer-reviewed journals.